BD, BioGX announce EUA submissions for COVID-19 dx

Create PDF

March 18, 2020—BD and BioGX have submitted emergency use authorization requests to the FDA for new diagnostic tests that, if authorized, would increase the potential capacity to screen for COVID-19 by thousands of tests per day. The tests will be run on the BD Max molecular diagnostic platform, which can process 24 samples simultaneously. Samples can be analyzed from start to finish in two to three hours.